Dec 20,2021

Contributed: Prescription digital therapeutics don’t need a physician

Prescription digital therapeutic products can improve health for the underserved, especially in the area of mental health. Apart from addressing the severe shortage of mental health professionals by increasing access to care, recent science would suggest the digital therapeutic modality can be particularly effective at treating widespread conditions, including those made worse by the pandemic.

#pdt

View Analyst & Ambassador Comments
Go to original news
Dec 21,2021

Podcast: How digital therapeutics can improve behavioral health

Benjamin Alouf, M.D., Chief Medical Officer of Limbix, talks about how can we utilize the PDTs to offer more immediate solutions to better meet the needs of the patients wiht mental health problems.

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 08,2021

Blue Note Therapeutics Partnering with Patient Advocacy Groups to Provide Digital Cancer-Related Mental Health Care During Pandemic

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics (PDTs) to help reduce anxiety, depression, and other forms of cancer-related distress. COVID Cancer Care is a stress management program which uses cognitive behavioral therapy and relaxation therapy. Since launch, nearly 12,000 people across the United States have accessed the program, which is currently available through more than 20 nonprofit and advocacy organizations, including Cancer Support Community.

PRODUCT

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Jan 06,2021

Mind Cure releases mental health digital therapeutic for psychedelic research

Mind Cure, a Canadian mental health company, has released a digital therapeutic tool designed to close the gaps between patients, clinicians and researchers. Called iSTRYM, the app provides close to real-time data regarding patient care, procedures and protocols. It’s described as a centralized management system that can be used for a variety of mental health treatments, including those in psychedelic therapeutic research.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 12,2021

Ehave Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant That Will Revolutionize Mental Health in Psychedelic Sector

Ehave, a leader in digital therapeutics, announced it has licensed revolutionary AI to unlock the human voice as a meaningful measurement of health. The AI technology is a mobile app that is a mental health monitoring tool based on voice tone and context analysis. Characteristics of the human voice, such as voice tone and context analysis, are what medicine labels vocal biomarkers.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 13,2021

Recover Together Teams Up With Pear Therapeutics To Provide People In Recovery Access To Innovative Treatment

Recover Together, Inc. (“Groups”), a leading outpatient treatment provider serving individuals with OUD across eight states, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced a combined effort to treat OUD patients by providing them with Pear’s innovative technology as well as Groups’ innovative approach to treatment. The undertaking will pair Groups’ differentiated clinical, full-virtual model that leverages the benefits of medication-assisted treatment (MAT) and high quality group counseling, and Pear’s reSET-O®, an FDA-authorized PDT intended to increase retention of patients with OUD in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management.

COLLABORATION PARTNERSHIP

#product & service

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 13,2021

Novartis trial shows no benefits from Pear's schizophrenia app as CEO cites trial irregularities

Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture. The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the app's safety, as very few significant adverse effects were reported.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 15,2021

Pear Therapeutics inks deal with digital pill company etectRx

Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry. The exact details of what a combined product will look like is still forthcoming. However, we do know it will be focused on the mental health space. Pear has previously released a slew of mental health-focused offerings, including one for opioid abuse disorder, substance abuse disorder and chronic insomnia.

COLLABORATION PARTNERSHIP

#product & service

#pdt

View Analyst & Ambassador Comments
Go to original news
Feb 03,2021

Highmark expands access to Freespira’s DTx

Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira‘s digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms. In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from a behavioral health professional, according to the announcement.

COLLABORATION PARTNERSHIP

#insurance

#telehealth

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 10,2021

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

Orexo AB today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. modia™, offers individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer.

COLLABORATION PARTNERSHIP

#r&d

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH